-+ 0.00%
-+ 0.00%
-+ 0.00%
Black Hawk Acquisition closes deal with Vesicor Therapeutics
Share
Listen to the news
Black Hawk Acquisition closes deal with Vesicor Therapeutics
  • Vesicor Therapeutics completed its previously announced combination with Black Hawk Acquisition on November 19, 2026.
  • The combined company was renamed Vesicor Therapeutics Holdings, with common stock expected to begin Nasdaq Capital Market trading November 23, 2026, as “VESI.”
  • Led by CEO Michael Tolentino, Vesicor plans to advance its cancer therapy ecm-RV/p53 through IND-enabling studies toward an FDA submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Hawk Acquisition Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200800PRIMZONEFULLFEED9881936) on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending